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PERSPECTIVES IN BASIC SCIENCE
Synthesis and effects of active fragments of angiotensin II
RAYMOND ARDAILLOU and DoMINIQuE CHANSEL
For a long time it has been assumed that the effects of the
renin-angiotensin system on the vessels, the adrenals, the brain
and the kidney resulted from the interaction of angiotensin II
(Ang II) with its receptors. Two renin-angiotensin systems, plas-
matic and tissular, have been described. Regulation of the plas-
matic system occurs at the stage of renin secretion as shown by the
close relationship between plasma renin activity and plasma Ang
II. In contrast, regulation of the various tissular systems implies
both renin and converting enzyme, the latter component being
overexpressed in cell types other than the endothelium in various
pathological conditions. Until recently, Ang II and its N terminal-
deleted heptapeptide fragment, Ang III, were considered to be
the only bioactive agents. Shorter fragments were described as
devoid of any physiological interest. This assumption was based
on the impossibility of obtaining the classical effects of Ang II with
these fragments [1]. Newevidence indicates that the actions of the
renin-angiotensin system are mediated, in addition to Ang II, by a
variety of angiotensin peptides acting on multiple receptors. All of
these peptides arise from different degradation pathways of Ang
II and of its precursor, Ang I, involving various enzymes; there-
fore, these peptides and enzymes may be considered to play a role
in the regulation of the system equally with renin and converting
enzyme. Most tissues including the kidney and the vessels are the
source, target and degradation site of Ang II. This is particularly
evident in the proximal tubule where the Ang 11 concentration is
high (10 nmol/liter) reaching 500 to 1000 times that simulta-
neously observed in the plasma [2, 3]. Locally formed Ang II acts
on its neighboring receptors and is also hydrolyzed by several
brush border enzymes into shorter fragments, which in turn
activate their own receptors.
The aim of this review is, first, to examine the enzymatic
pathways of synthesis of the Ang II fragments and, second, to
analyze the cellular mode of action and the role of these frag-
ments mainly in the vessels and the kidney.
ENZYMATIC PATHWAYS OF PRODUCTION OF
ANGIOTENSIN II FRAGMENTS
Ang II can be hydrolyzed both at its N terminal and C terminal
ends. Its precursor, the decapeptide Ang I, can be similary
degraded (Fig. 1). The main enzymes playing a role in these
reactions are ectopeptidases including aminopeptidases A and N,
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angiotensin converting enzyme (ACE), prolylendopeptidase and
neutral endopeptidase (Fig. 2).
Enzymes acting at the N terminal end
Aminopeptidase A or angiotensinase A (L-a-aspartyl or L-cs-
glutamylpeptide hydrolase, EC 3.4.11.7) acts on peptides with an
N-terminal acidic amino acid such as Ang I, Ang II and the
cholecystokinin octapeptide. Angiotensinase (APA) is identical to
the murine /3-cell differentiation antigen, BP-1/6C3, which is
expressed on immature (3-lineage cells [4]. It converts Ang I into
Des Asp1 Ang I and Ang II into Des Asp1 Ang II, also referred to
as Ang III. High APA activity has been found in human and rat
glomeruli, essentially in podocytes [5—71, and in a single report in
mesangial cells [8]. There is also a positive APA reaction in the
brush border of the proximal tubule [6, 9]. Interestingly, admin-
istration to rats of antibodies against the APA antigen results in
proteinuria associated with a membranous-like glomerulonephri-
tis resembling that found in the model of Heyman nephritis [10].
Losartari and enalapril reduced this proteinuria, suggesting the
role of Ang II in this model [11].
Aminopeptidase N (APN, a-aminoacyl peptide hydrolase, EC
3.4.11.2) acts with a relatively broad substrate specificity on
peptides with an N-terminal neutral amino acid. Hydrolysis of
synthetic substrates (p-nitroanilides) shows the following order of
specificity: alanine > leucine > lysine> arginine > valine [121. Its
primary naturally occurring substrates are enkephalins, dynor-
phin, substance P, the thrombin receptor agonist peptide and Ang
III. It converts Ang III into the hexapeptide Ang IV. APN is
identical to CD 13 (gp 150), a cell surface glycoproteiri originally
identified on subsets of normal and malignant human myeloid
cells [13]. APN is widely distributed with a high density in the
renal cortex. Early histochemical studies detected a high activity
in the brush border of proximal tubules [14]. Using more sensitive
immunocytochemical techniques, APN was found to he present
both in glomeruli and proximal tubules on mouse renal sections
[6, 9]. Mesangial and proximal tubule cells in culture also express
APN [15, 16]. In the latter preparation, APN is considered as a
marker of the apical side of the cells [16]. Aminopeptidase B (EC
3.4.11.6) also cleaves peptides with an N terminal arginine.
Aminopeptidase B is only present in the cytosol and thus is likely
not to play any role in the degradation of the extracellular
peptides. However, it has been shown that Ang IV could be
produced by an endosomal pathway from Ang II that had been
internalized in bovine adrenal medullary cells. Ang IV is rapidly
released in the medium and can bind to specific receptors in an
autocrine or paracrine manner [17].
Aminopeptidases A and N have been cloned [18, 19]. They are
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Fig. 1. Sites of cteavage of Ang I and Ang II by
various enzymes. Abbreviations are: ACE,
angiotensin converting enzyme; APA,
aminopeptidase A; NEP, neutral
endopeptidase; PEP, prolylendopeptidase; DPA
III, dipeptidylaminopeptidase III; TOP, thimet
oligopeptidase; Chy, chymase; CPA,
carboxypeptidase A.
Angiotensin IV
Val — Tyr — lie — His — Pro — Phe
Fig. 2. Various enzymatic pathways of angiotensin I and angiotensin II degradation. Abbreviations are: ACE, angiotensin converting enzyme; APA,
aminopeptidase A; APN, aminopeptidase N; APB, aminopeptidase B; PEP, prolylendopeptidase; NEP, neutral endopeptidase; DPA III, dipepti-
dylaminopeptidase III; TOP, thimet oligopeptidase; CPA, carboxypeptidase A.
zinc metalloproteases belonging to the thermolysin-like enzyme
group with significant homologies in their amino acid sequence
and similarities in their physical properties (Table 1). Like neutral
endopeptidase and ACE, they possess a large glycosylated extra-
cellular domain that contains the catalytic sites. APA and APN
expressions appear to be, at least in glomerular epithelial cells,
under different regulations: mitogens, IFN-y and thrombin for
APN, cyclic AMP and glucocorticoids for APA [12]. APA and
APN are inhibited by naturally occurring compounds, essentially
bestatin and amastatin, which are microbial products [20, 211 and
have been extensively utilized. However, both agents interact
nonspecifically with all the enzymes of the aminopeptidase family
with inhibitor potencies in the micromolar range. Recently, potent
and selective inhibitors of APA and APN have been designed. In
the case of APA, the best reported inhibitor is the compound EC
33 [(R.S)-3-amino-4-thiol-butyl-sufonatc], which has a K1 of 0.29
jLM and a selectivity factor toward APN around 100 (K1 of 25 /.LM
with APN) [22]. Concerning APN, the disulfide forms of 13-
aminothiols were found to be efficient prodrugs of inhibitors. For
example, the compound PC 18 inhibits APN with a K1 of
approximately 0.01 J.tM [231. These new agents represent invalu-
able new tools to ascribe a physiological effect to a given Ang II
fragment. For example, any effect inhibited by EC 33 and
potentiated by PC 18 can he attributed to Ang III. Similarly, any
effect inhibited by PC 18 can be attributed to Ang IV. This
represents real progress with respect to bestatin and amastatin,
which inhibit APA and APN equally.
There is also the possibility of the direct formation of Ang IV
from Ang II by cleavage of the N-terminal Asp-Arg dipeptide in
the presence of dipeptidylaminopeptidase III (EC 3.4.14.4). This
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Table 1. Characteristics of aminopeptidases A and N
Aminopeptidase A Aminopeptidase N
Corresponding blood murine B cell CD 13 antigen
cell antigen differentiation
antigen BP-1/
6C3
Natural occurring Ang II, enkephalins, substance P,
substrates cholecystokinin
octapeptide
Ang III, dynorphin,
thrombin receptor
associated peptide
Substrate specificity glutamic acid, alanine > leucine >
(N terminal amino aspartic acid arginine
acid)
Inhibitors bestatin, amastatin,
EC 33
bestatin, amastatin,
disulfide forms of f3
aminothiols
Regulation of glucocorticoids, mitogens, IFN-y,
expression cyclic AMP thrombin
Renal distribution brush border of
the proximal
tubule,
glomerular
epithelial and
mesangial cells
brush border of the
proximal tubule,
glomerular mesangial
cells, apical pole of the
principal cells of the
collecting duct
enzyme was partially purified from rat brain [24]. Due to its
cytosolic distribution, it is likely that it is not involved in the
catabolism of extracellular Mg II.
Enzymes acting at the C terminal end
The best known enzyme acting at the C terminal end is
angiotensin converting enzyme (ACE) (EC 3.4.15.1), a zinc
metalloprotease that transforms Ang I into Mg II by deletion of
the dipeptide His9-Leu'°. It can also, by hydrolysis of the same
bond (Phe8-His9), convert Des Asp' Mg I into Ang III. Since this
enzyme has been extensively studied, it will be considered briefly
hereafter. More information can be found in previously published
reviews [25, 26]. Two ACE isoforms, somatic and germinal, exist
in mammals. Somatic ACE is a polypeptide including two catalytic
active sites with close affinities for their substrates [27]. Within
kidney, ACE has been localized to glomerular endothelial cells
and proximal tubule brush border [28]. Like APA and APN, it is
an ectoenzyme. Protease activity releases the endothelial enzyme
into the circulation, which allows ACE activity to be measured in
the plasma. In addition to Ang I and Des Asp' Mg I, ACE
cleaves a variety of substrates, in particular bradykinin. The
germinal form of ACE is only expressed in the developing male
germ cells of the testis. Germinal ACE is approximately half the
size of somatic ACE and possesses only one catalytic site. Its
function in the development of the male germ cells and the
associated role of the various components of the renin-angioten-
sin system have not been clearly defined. The human ACE gene
includes two promoters, (1) somatic, localized on the 5' side of the
first exon, and (2) germinal, which is intragenic with highly
contrasting cell specificities. An ACE gene polymorphism has
been described. It consists of the presence or the absence of a 287
base pair DNA fragment that is localized in intron 16. The
subjects who are homozygous for the deletion (DID) have ACE
plasma levels almost twice as high as those homozygous for the
insertion allele (I/I). Intermediaiy results are observed in the
heterozygous (l/D). This ACE gene polymorphism does not play
a major role on blood pressure variance in the population.
Moreover, intravenous administration of Mg I in I/I and DID
subjects did not provide different effects concerning Mg II
formation and blood pressure increase [29, 30], which suggests
that ACE has no limiting influence on the formation of plasma
Ang II. Contradictory results were reported by Ueda et al [30] but
under different experimental conditions (in particular, without
inhibition of the endogenous production of Ang I). It is likely that,
in contrast to plasma Mg II, tissue Mg II formation depends on
the local abundance of ACE, as suggested by the fact that the D/D
polymorphism appears to be correlated with the frequency of
cardiovascular ischemic diseases and renal sclerosis [31]. This
strongly suggests a role for the various tissue renin-angiotensin
systems in the development of atherosclerosis and fibrogenesis.
Moreover, any effect on ACE activity may cause repercussion by
diverting the pathway of Mg II formation from Mg I into other
pathways such as Mg (1-7) formation. This side effect of ACE
inhibitors has also to be taken into account when explaining their
mechanism of action.
Chymases are a family of mast cell serine proteinases that are
involved in peptide hormone processing [32]. In mammalians
there are two distinct isoenzyme groups of chymases. Human
chymase belongs to the a group. It plays a crucial role in the heart
in the formation of Mg II from Mg I by splitting the Phe8-His9
bond (80 to 90% of the Mg 11-forming activity). In contrast, rat
chymase-1 is a J3 chymase. It behaves as an angiotensinase because
it splits the Tyr4-11e5 bond in angiotensins I and II with a 20-fold
higher catalytic efficiency than the Phe8-His9 bond [33]. Chymases
are synthesized as inactive precursors but are stored in secretory
granules as active enzymes. Most of the secreted chymases in the
heart have been found to be localized to the extracellular matrix.
The Pro7-Phe8 bond of Mg I and Mg II can be cleaved by
prolylendopeptidase (EC 3.4.21.26), which has a relative molecu-
lar mass of 70,000 and belongs to the family of serine proteases.
This reaction results in the formation of Mg (1-7). Prolylen-
dopeptidase has been purified from the rat and pig kidneys [34]
and is inhibited specifically by Z-prolyl-prolinol [35].
Since inhibition of prolylendopeptidase does not prevent the
generation of Ang (1-7) in many tissues, other enzymes capable of
catalyzing the formation of this peptide must exist. Neutral
endopeptidase (EC 3.4.24.11) seems to be the most important.
Like ACE, this enzyme has been extensively studied and will not
be considered in detail in the present review. Neutral endopepti-
dase degrades both natriuretic peptides and kinins. It also hydro-
lyzes Mg II at the Tyr4-11e5 bond to yield Mg (1-4) [36].
Moreover, it facilitates the direct conversion of Mg I into Mg
(1-7) by splitting off the C terminal tripeptide Phe-His-Leu from
Mg I [32]. Neutral endopeptidase is a 90 kDa ectoenzyme that is
present in brush border of proximal tubule cells, glomerular
podocytes and renal cortical vessels. It can be specifically inhibited
by thiorphan and related agents. Interestingly, metabolic path-
ways contributing to the generation of angiotensin fragments by
hydrolysis of the C terminal part of the peptide are tissue specific.
For example, Yamamoto et al [37] showed that in vivo conversion
of Mg I into Mg (1-7) in the rat depended only on neutral
endopeptidase, whereas prolylendopeptidase accounted for 40%
of the Mg (1-7) generating activity in other preparations [38].
A fourth enzyme, metallopept lase EC 3.4.24.15 (thimet oh-
gopeptidase), has been described n vascular smooth muscle cells
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Table 2. Renal, metabolic and vascular effects of Ang II and its active
fragments
Biological responses Ang II Ang Ill Ang IV Ang (1-7)
Thirst / / - -
Salt appetite / 1' — —
AVP secretion 7 7 — 7
Aldosterone secretion ," 7 — —
Catecholamine secretion 7 7 — —
Renal plasma flow \ — 7 —
Glomerular filtration rate \ — — 7
UrinaTy sodium excretion N — — 7
Cytosolic calcium in renal cells 7 — 7 —
Vasoconstriction 7 — — N
Smooth muscle cell growth 7 — — N
and has been found to be able to convert Ang I into Ang (1-7)
[39J.
Finally, carboxypeptidase A, which splits the His'-Leu'° bond
of Ang 1, must be included in this group of enzymes acting at the
C terminal end. Its main source is the mast cells [40] and the
product of the reaction is Ang I (1-9). Mast cells are present
particularly in the heart where they synthesize chymase [321.
Carboxypeptidase A and chymase thus appear to contribute to the
specificity of the human cardiac tissue for angiotensin formation
and metabolism.
IN VIVO AND IN VITRO EFFECTS OF THE ANGIOTENSIN
ACTIVE FRAGMENTS
Fragments obtained by deletion of the N terminal end of
angiotensin peptides: Angiotensin III and angiotensin IV
Ang III. It is generally accepted that Ang III exerts its effects via
the specific Ang II receptors, AT1 and AT2. Initial studies showed
that Ang III had a lower affinity than Ang II for Ang 11-binding
sites [41], and that intravascular injected Ang III was much less
potent than Ang II in eliciting biological responses. For example,
the pressor effect of Ang Ill was ten times less potent than that of
Ang II [42]. The reason for this difference was attributed to the
differential catabolic rate of these peptides by the peripheral
tissues [43]. The metabolism of '251-Ang III has been found nearly
three times faster than that of 'I-Ang-I1 [44]. This is due to the
broad distribution of APN that initiates the hydrolysis of Ang III,
but not of Ang II; it was confirmed by administering bestatin or
amastatin, which restored a full vasoconstrictory effect for Ang Ill
in rabbit isolated thoracic aorta [42]. Similarly, the lower potency
of Ang Ill to displace ['25l]-Ang II binding from pig aorta
receptors could be related primarily to Ang 111-specific degrada-
tion and was restored by amastatin [45]. Recently, Wolf, Assmann
and Stahl observed that overexpression of APA abolished the
growth promoting effect of Ang II in cultured mesangial cells [46].
This could suggest the inability for Ang III, in contrast with Ang
II, to be mitogenic. Alternatively, it could be the consequence of
the rapid destruction of both active peptides by the successive
effects of overexpressed APA and constitutively expressed APN.
In other systems, Ang lit is as potent as or, even, more potent
than Ang II. This is the case for the steroidogenic activity of Ang
III in the adrenal cortex, which is equal to that of Ang II (Table
2) [41]. Both peptides also similarly affect norepinephrine uptake
and release in the rat adrenal medulla [47]. Angiotensin III and
Ang II share most of their effects in the central nervous system. At
low doses, Ang III administered intracerebroventricularly pro-
duces an equipotent pressor response and dipsogenicity compared
with Ang 11 [48]. Similarly to Ang 11, it also modifies central
sympathetic activity via modulation of noradrenergic neurotrans-
mission at the presynaptic sympathetic nerve endings, as shown by
its stimulatoiy effect on noradrenaline uptake and release in the
rat hypothalamus [49]. This confirms that the central actions of
Ang III, like those of Ang II, could be mediated in part by brain
catecholamines. Angiotensin III and Ang II both stimulate vaso-
pressin and adrenocorticotrophin release [50], but recently Zini et
al [51] showed that conversion of Ang II to Ang III was required
to stimulate vasopressin secretion in mice, Indeed, the Ang II
effect was suppressed by an APA inhibitor whereas it was
reinforced by an APN inhibitor. In favor of a specific role for Ang
111 is also the fact that Des Asp' Ang I-induced drinking was
abolished by captopril, an inhibitor of ACE, suggesting that its
conversion to Ang 111 was a prerequisite for dipsogenicity [52].
These results raise the question of specific receptors for Ang III.
The absence of selective localization of Ang III in the brain as well
as the inhibition of Ang Ill effects by the AT, antagonists and the
cross-desensitization of [Ca2] responses to Ang III and Ang II in
rat nephron segments [53] suggest a negative response. The major
role of Ang Ill in the brain is more likely to be due to its
predominance, as demonstrated by Harding et al [54], who found
that 93% of the Ang release in the paraventricular nucleus, after
stimulation by veratridine or water deprivation was represented
by Ang Ill. Such predominance of Ang III could also occur in
other tissues as the result of APA overexpression under patho-
logical conditions including subtotal nephrectomy [55] and diabe-
tes mellitus [56]. For all these reasons, the opinion that Ang III
could have specific receptors is unlikely and is advanced only by a
limited number of authors. For example, Sim and Yuan [57]
recentlysuggested that Ang II and Ang III acted on separate
subclasses of vascular Ang receptors that were differently modu-
lated by Des-Asp Ang I.
Whereas Ang III binds to AT1 with an affinity equal to or lesser
than that of Ang II, it has been reported to bind preferentially to
the AT2 group of Ang II receptors [58]. Therefore, inhibition of
APA would favor binding of Ang II to AT1 receptors whereas
overexpression of APA would shift binding to AT2 receptors. The
latter class of receptors is not predominant in the adult kidney, but
is essentially present in the big vessels [59] and the glomerular
endothelium where it induces the synthesis of the chemokine
RANTES, a strong chemoattractant substance for macrophages!
monocytes [60].
Ang IV. The assumption that Ang IV had no biological activity
and was therefore of minor importance was based on two lines of
evidence: (I) The two classes of Ang II receptors, AT, and AT2,
display veiy poor affinities for Ang IV [61, 62]; (2) Ang IV
administration does not elicit the well known Ang 11-dependent
effects in contrast with Ang III [1, 63]. These facts were at first
unanimously accepted, but supplementary data led to a novel view
of the role of Ang IV. First, specific binding sites for '251-Ang IV
have been found in different tissues [62, 64, 65] that are pharma-
cologically distinct from the classical AT1 and AT2 and differently
distributed (Fig. 3). Second, the functions mediated by these
receptors are not related to the AT1 and AT2 functions that had
been already described [66, 67]. Third, some effects of Ang II are
suppressed in the presence of APA or APN inhibitors, or both,
which suggests that these effects are not due to Ang II but to its
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A targets is relatively high when compared to that of Aug II. The
order of potency of the various angiotensin peptides as competi-
tors for Aug IV is the following: Ang III > Ang 11(3-7) > Ang II
(3-6) > Ang II > Ang 11(4-8) > Ang 11(1-7). The high affinity of
Ang III toward Ang IV binding sites is, in fact, due in most cases
to the rapid transformation of Ang III into Ang IV. The nonpep-
tide AT1 (losartan, EXP 3174, CV 11974) or AT2 (PD 123177, PD
123319) antagonists do not affect Ang IV binding [61, 63, 64, 681.
Guanosine triphosphate or its analogs also do not influence Ang
IV binding [69, 70], except in opossum kidney cells [71]. The
divalent cations, Mg2 and Ca2, diminish the binding of [125I]
Ang IV [69] whereas ethylenediaminetetraacetic acid, a calcium
chelator, and dithiotreitol increase its binding affinity [72, 73].
Studies on the relationships between structure and activity
using various peptidic analogs have allowed the main criteria of
selectivity of the AT4 receptors to be established [58, 691. These
studies indicated the important role of the N terminal valine, and
more precisely of a primary a-amine and a L-conformation in
position number 1 in the binding process. Cleavage, methylation
or cyclization of this amine resulted in an important reduction of
affinity. An aromatic amino acid also seems to be necessary in
position number 2 in order to maintain a high affinity binding to
the receptors. The C terminal amino acids (positions 4, 5 and 6)
are more flexible and may be replaced by other amino acids
without major consequences. Sequential deletion of these C
terminal amino acids results in a progressive decrease of affinity
that, however, persists for the N terminal tripeptide Val-Tyr-Ile
[58]. A specific antagonist of Ang IV, divalanal-Ang IV, has been
designed by replacing the amide bond connecting the Val' and
Tyr2 residues with a methylene bond isostere (CH2-NH) [74]. Of
note, Moeller et al [75] reported that a decapeptide (Leu-Val-
Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe) isolated from sheep brain
bound to the AT4 receptor with an affinity similar to that of Ang
IV. This peptide is identical to the amino acid sequence 30-39 of
sheep /3 globin and has previously been named LVV-hemor-
phin-7. It belongs to a family of globin fragments that can be
obtained in vitro by enzymatic digestion. These compounds exhibit
opioid actions [761, and noncompetitively inhibit ACE [77]. Their
physiological role and, in particular, their possible influence on
the renin angiotensin system remain to be elucidated.
The signal transduction after activation of the Ang IV binding
sites is still debated with results varying from preparation to
preparation. Bernier et a! [69] reported that cytosolic calcium,
inositol phosphate, cAMP and arachidonic acid concentrations
did not change in endothelial cells after stimulation by high
concentrations of Ang IV. In contrast, Dulin et a! [71] found an
increase in intracellular calcium concentration after treatment of
opossum kidney cells by Ang IV. Czekalski et al [65] observed an
increase in cAMP production in collecting duct principal cells, but
only in the presence of forskolin, an activator of adenylate cyclase.
Ang IV receptor molecular structure is unknown. The fact that, in
most studies, Ang IV binding is not inhibited in the presence of
guanylnucleotides suggests that Ang IV receptor does not belong
to the seven transmembrane domain receptor family. The molec-
ular weight of Ang IV receptor has been deduced from its partial
purification after covalent linkage with disuccinimidyl suberate
[69]. The predominant band observed in a polyacrylamide gel
corresponded to an apparent molecular weight of 186 kDa. There
were less marked heavier bands that could represent multimeric
forms. Possible dimerization of the receptor suggests that it may
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Fig. 3. (A) Comparative inhibition of binding of [1251]-Ang IV to collect-
ing duct cell membranes in the presence of increasing concentrations of
Ang IV (•),Ang III (0), Ang II (LI), Ang 11(4-8) (Li) and Ang 11(1-7) (A).
(B) Lack of competitive effect of losartan (LI), an AT1 antagonist and of
PD 123177 (A), an AT2 antagonist, on [ '251]-Ang IV binding to collecting
duct cell membranes (From Czekalski et al, Kidney mt 50:1125—1131, 1996;
used with permission).
metabolites [68], AT4 receptors share common characteristics in
the brain and peripheral tissues including adrenals, vascular
smooth muscle, kidney, gut, prostate and endothelium [reviewed
in 58]. Their apparent dissociation constant for Ang IV is in the
nanomolar range and their density at the surface of their cell
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resemble growth factor or cytokine receptor. Such an hypothesis
is also supported by studies using a photoprobe [581. Gel analysis
of solubilized receptors from several sources indicated that the
AT4 receptor was present in both monomeric (165 kDa) and
heterodimeric forms.
Angiotensin IV is present in blood at lower concentrations than
Ang II [781. It is also formed locally in the brain and the
peripheral tissues where it exerts pleiotropic effects. Adminis-
tered in the cerebral ventricules, it activates neuronal pathways
implicated in learning, memory and exploratory behavior [67].
Ang IV increases cerebral blood flow, but at higher doses
compared with those of Ang II, it causes a reduction [58]. Topical
application of both Ang II and Ang IV causes endothelium-
dependent vasodilation in rabbit brain arterioles. Since the vas-
cular response to Ang II, but not that to Ang IV, was completely
blocked by amastatin, this effect could be attributed to Ang IV
[79]. Ang IV is also vasodilatory in the renal circulation in contrast
with Ang Ii [66]. However, it behaves as a vasoconstrictor in other
vascular beds including the pulmonary circulation in the cat [80]
and in the rat [81] as well as the hindlimb vascular bed in the rat
[821. These opposite results are probably due to the fact that Ang
IV may mimick some Ang TI effects due to its low affinity toward
AT1 receptors. This conclusion is confirmed by the inhibitory
effect of losartan on Ang TV-dependent vasoconstriction. In
contrast, the vasodilatory effects of Ang IV are likely to be
mediated by the AT4 receptors. The fact that intracerebroven-
tricularly administered APN results in hypotension in spontane-
ously hypertensive rats suggests a physiological role for Ang IV in
the control of blood pressure [83]. The effects of Ang IV have also
been studied in in vitro systems. Several studies concluded that
Ang IV caused cell hypertrophy and hyperplasia either alone [84]
or in cooperation with other growth factors [58]. In particular,
Ang IV could contribute to cardiac hypertrophy by stimulating
RNA and DNA synthesis in cardiac fibroblasts [84]. In contrast,
Ang IV antagonized Ang Il-induced increase in RNA and protein
synthesis in chick heart cells [85]. in addition to its effect on cell
growth, Ang IV has been shown to stimulate the synthesis of
protooncogenes such as c-Fos [86] and of specific proteins. In this
regard, the well-known stimulatory effect of Ang Ii on the
inhibitor of type I -plasminogen activator (PAT-i) could be attrib-
uted to Ang IV. Indeed, the effect of Ang TI was suppressed by
bestatin, and Ang IV itself stimulated dose- and time-dependent
increases in the expression of PAT-i mRNA in cultured endothe-
hal cells [68].
Fragments obtained by deletion of the C terminal end of
angiotensin peptides: Angiotensin 11(1-7) and angiotensin II
(3-7)
Angiotensin 11 (1-7. This Ang IT fragment was identified in the
plasma and a variety of tissues of many species including humans
at concentrations similar to or even higher than those of Ang TI.
For example, it is the major product of Ang I metabolism in
human and dog kidneys [87, 88] and in porcine proximal tubule
membranes [89]. Moreover, Ang II (1-7) plasma concentration
was found to increase after treatment by an AT1 antagonist [90] or
an ACE inhibitor [911. Ang 11(1-7) was initially thought to be an
inactive fragment since it did not reproduce the vasoconstrictor,
dipsogenic and aldosterone-secreting effects of Ang II [92]. It is
now believed that Ang 11(1-7) is a biologically active peptide with
properties that are distinct from those of Ang II and even often
opposite to them. These biological effects are mediated by a
specific non-AT1, non-AT2 receptor and are, in part, indirect since
they often require the initial formation of prostaglandins and/or
nitric oxide (No). The characteristics of the Ang 11(1-7) receptors
have been described in several preparations [93, 94]. In a recent
study, Tallant et al [94] reported that cultured bovine aortic
endothelial cells contain a saturable, high-affinity Ang 11(1-7)
binding site with an affinity close to 20 nM and a density of 1350
fmol/mg protein. There was also a low affinity binding site
corresponding probably to an enzyme. Ang 11(1-7) binding was
not inhibited by the AT1 or AT2 antagonists. In contrast, it was
prevented by a nonselective Ang II antagonist, Sar', 11e8, Ang II.
Interestingly, ['2I]-Ang 11(1-7) binding to cultured endothelial
cells was completely inhibited by D-A1a7-Ang 11(1-7) with an IC50
value similar to the K0 value (20 nM). This peptide behaved as a
specific antagonist of Ang 11(1-7) binding since it did not compete
for Ang II binding to rat adrenals [95]. Ang II itself also competed
for ['25I]-Ang 11(1-7) binding but with an IC0 value (130 nM)
higher than the K0 value. This indicates that the Ang 11(1-7)
receptor recognizes Ang II, but at higher concentrations than Ang
II (1-7). Conversely, Ang II (1-7) at high concentrations can
compete with Ang TI for angiotensin receptors [96], which ex-
plains the finding that losartan is capable of blocking some Ang TI
(1-7) effects, including the release of [3H]—noradrenaline from rat
atria [97], the decrease in fluid absorption in the proximal tubule
[95], and the decrease of renal blood flow [98, 991 In agreement
with these results, Mahon et al [100] showed that Ang 11(1-7)
behaved as a specific noncompetitive antagonist of Ang II at its
AT1 receptor sites on rabbit aortic rings. Inhibition by AT1
antagonists of Ang 11(1-7) effects obtained at low concentrations
has been also, but more rarely, reported [98] leaving still open the
question of the possible heterogeneity of Ang 11(1-7) binding
sites.
Ang 11(1-7) exerts effects in the kidney, the vessels and the
brain (Table 2). In contrast to the vasoconstrictor effects of Ang
II, it acts as a vasodilator agent in many vascular beds including
porcine and canine coronary arteries [101, 102], porcine pial
arterioles [100, 103] and feline mesenteric arteries [104]. The
resulting inhibitory effect on the vascular resistance explains why
Ang II (1-7) reduces blood pressure in spontaneously hyperten-
sive rats [105] and dogs with a renovascular hypertension [106]. In
transgenic (mRen-2) hypertensive rats, central administration of
antibodies to Ang 11(1-7) produced hypertensive effects whereas
antibodies to Ang II were hypotensive [107]. Furthermore, Ang II
(1-7) activates antihypertensive mechanisms in response to Ang II
administration by increasing the sensitivity of the baroreceptor
reflex [108]. Ang 11(1-7) has little influence on the renal vascu-
lature and is devoid of renal hemodynamic effects at doses that
are effective in the case of Ang II [99]. Ang 11(1-7) also opposes
the proliferative effect of Ang II since it inhibits the vascular
smooth muscle cell growth [109]. In contrast to its lack of effect on
renal vascular resistance, Ang 11(1-7) produces a marked increase
in renal sodium and water excretion [99]. This is another indica-
tion of the opposite effects of Ang II and Ang 11(1-7). The
heptapeptide increases urinary output and electrolyte excretion
rates. Multiple targets are involved in the action of Ang 11(1-7) on
the kidney. First, it decreases fluid and bicarbonate reabsorption
in the proximal straight tubule at high concentrations (10 nmol/
liter) whereas it has opposite effects at lower concentrations (1
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pmol/liter) [98]. Second, Ang 11(1-7) inhibits oxygen consumption
in the rat proximal tubule which is associated with a decrease in
Na,K-ATPase activity [99]. Third, Ang 11(1-7) possesses a
potent peripheral antidiuretic activity in water-loaded rats that is
abolished after treatment with an anti-Ang II (1-7) antagonist
[110]. Fourth, Ang II (1-7) causes a modest but significant
increase of glomerular filtration rate [1111. However, it has been
shown that natriuresis and diuresis were independent of an
increase in the glomerular filtration rate [112]. Both effects are
also independent of renal innervation since they have been
reported in denervated kidneys in vivo [99] and in in situ perfused
rat kidneys [112]. Taken together, these results are in favor of an
effect of Ang 11(1-7) on sodium and water transport irrespective
of any hemodynamic change. This is confirmed by the 20%
inhibition of Na flux in cultured renal epithelial cells [113]. The
physiological role of Ang 11(1-7) in the control of hydromineral
balance is also suggested by the increase of its circulating levels in
chronically salt-loaded rats [114], in opposition to what is ob-
served for Ang II. Ang 11(1-7) also influences the hydroelectro-
lytic balance via its actions on the brain including stimulation of
arginine vasopressin release [115] and increase of neuronal activ-
ity [116]. These data are in agreement with the dense immuno-
staining for Ang 11(1-7) found in the supraoptic and paraven-
tricular nuclei of the hypothalamus [117].
The complexity of the effects of Ang II (1-7) results from
addition of direct effects of the peptide to other effects that are
mediated by prostaglandin E2 (PGE2), prostaglandin 12 (PGI2) or
nitric oxide. Jaiswal et al [118] reported that Ang II (1-7)
stimulated the release of PGE2 and PG!2 in a dose-dependent
manner (100 pmollliter to 1 jsmol/liter) with an EC50 of approx-
imately 1 nmol/liter in porcine aortic endothelial cells. Similar
effects were observed in other preparations including rat smooth
muscle cells [119], human astrocytomes [120], glioma cells [121]
and rabbit vasa deferens [122]. Whereas Ang 11(1-7) was consid-
erably more potent than Ang II in stimulating prostaglandin
release from cultured endothelial cells, it exhibited a similar
potency in the latter three preparations. Ang 11(1-7) influences
Fig. 4. Effects of angiotensin converting
enzyme inhibition by endogenous products or
drugs. Inhibition results in decrease of Ang II
formation, protection of kinins and increase of
Ang (1-7) formation due to increased
availability of Ang I.
prostaglandin synthesis via stimulation of arachidonic release as
shown in isolated proximal tubule epithelial cells [113]. This
stimu!atory effect of Ang I! (1-7) on prostaglandin production was
also observed in vivo since chronic infusion of the heptapeptide
increased urinary prostaglandin excretion in hypertensive animals
[105]. Because PGE2 and PGI2 are known to inhibit sodium
reabsorption in the ascending limb of Henle's loop and water
reabsorption in the collecting duct, it could be suggested that such
effects of Ang 11(1-7) were mediated by both prostaglandins. This
hypothesis has been confirmed, at least in part, by Hilchey and
Bell-Quilley [111] who showed that indomethacin, a cyclooxygen-
ase blocker, halved the fourfold increase in urine flow and
sevenfold increase in sodium secretion rate obtained after Ang II
(1-7) infusion in the rat. It has been also hypothesized but not
demonstrated that the epoxyeicosatetraenoic acids (EET) derived
from arachidonic acid via the P450-dependent monooxygenase
pathway could be involved in the biological activity of Ang I! (1-7)
in the proximal tubule [96]. Another intermediate factor for Ang
11(1-7) action is nitric oxide (NO). Indeed, Ang 11(1-7) stimu-
lated the release of NO in porcine coronary endothelium [102]
and elicited NO-dependent vasodilation in coronary artery rings
[101]. More recently, Li et al [1231 studied the interaction beween
Ang 11(1-7), NO and bradykinin. They showed that Ang (1-7)
augmented the vasodilation induced by bradykinin in intact canine
coronary artery rings and that this effect was abolished by a
pretreatment with N-nitro-L-arginine, a NO synthase inhibitor.
The mechanism implied is an inhibition of ACE activity in the
presence of an excess of Ang II (1-7), thus preventing the
degradation of kinins and augmenting kinin levels which in turn
stimulate NO production. Inhibition of ACE by Ang 11(1-7) was
confirmed in vitro using purified ACE from canine lungs. This
property of Ang 11(1-7) may explain in part its antihypertensive
effects (Fig. 4).
Angiotensin II (3-7). This peptide is produced in mammalian
brain [38, 124]. Ang (3-7) represents the shortest Ang II fragment
having psychoactive properties. Together with its substituted
analog Leu-5, Ang (3-7) improves recognition but not spatial
Ang II 1
Ang (17)/ /
NO, eicosanoids/
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memory in rats that have been given 1 nmol of either peptide
intracerebroventricularly [1251. The receptors involved in this
effect have not been clearly determined. Although AT4 sites are
probably mostly implicated, AT1 sites cannot be excluded since
losartan has been shown to prevent facilitation of object recogni-
tion both by Ang II and Ang 11(3-7) [126].
Other angiotensin fragments
The Ang III sequence includes several fragments that have
been shown to possess in vitro anti-ACE activity. Four fragments
with ACE inhibiting activity, Val-Tyr (Ang 3-4), Ile-His-Pro-Phe
(Ang 5-8), Tyr-Ile-His-Pro-Phe (Ang 4-8) and Ang IV were
generated after incubation of Ang III with plasma from sponta-
neously hypertensive rats [127]. Val-Tyr and Ang III when
injected intravenously in these rats produced a fall in diastolic
blood pressure. The hypotensive effect of Ang III was attributed
to its metabolites via inhibition of ACE activity. Ang I can also
give birth to an endogenous inhibitor of ACE, Ang 1 (1-9) by
splitting of its C terminal bond, His9-Le&°. The responsible
enzyme is a carboxypeptidase. Ang I (1-9) is present at low
concentrations in human and rat plasma as well as in rat kidney
[128], and has been found to competitively inhibit ACE [128].
Interestingly, a decapeptide isolated from sheep brain and iden-
tical to LVV-hemorphin 7, a fragment of f3 globin, competes with
Ang IV for the AT4 receptor [75] and also inhibits ACE activity
together with other hemorphins [77]. Therefore, both Ang active
fragments and other naturally occurring fragments of different
origin but with a related structure could contribute to ACE
inactivation and, via this mechanism, to the overall regulation of
the renin-angiotensin system.
CONCLUSIONS
The demonstration that Ang I and Ang II fragments exert
biological effects has markedly modified our views on the final
effectors and the regulation of the renin-angiotensin system. The
following new points have to be now considered: (1) There are
several pathways for degradation of Ang I bypassing converting
enzyme and of Ang II leading to different fragments, which raises
the question of the relative importance of these pathways and of
their degrees of control; (2) Ang II fragments may act via
activation of their own receptors [Ang IV and Ang 11(1-7)] or via
inhibition of ACE activity; (3) Many of their effects, except for
Ang III, are opposed to the AT1 -mediated effects of Ang II since
they include hypotension, sodium and water excretion and inhi-
bition of cell growth; (4) New tools are rapidly being developed
that will allow the pharmalogical control of their production
(APA and APN inhibitors) or of their effects (antagonist).
Reprint requests to Dr. R. Ardaillou, INSERM 64, Hôpital Tenon, 4 rue de
In Chine, 75020 Paris, France.
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